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AUTOPHAGY, PHYSIOLOGY AND CELL PATHOLOGY 
Maria I. Vaccaro 
Institute for Biochemistry and Molecular Medicine, CONICET, School of Pharmacy and Biochemistry, 
University of Buenos Aires, Buenos Aires, Argentina (mvaccaro@ffyb.uba.ar) 
 
Autophagy plays an important role in human pathologies, such as myopathies and 
neurodegenerative diseases. Moreover, metabolic disease processes such as diabetes 
and pancreatitis, as well as tumor cells and cancer chemotherapy, activate autophagy. 
Furthermore, a selective type of autophagy of pancreatic zymogen granules has been 
discovered and characterized as a protective cellular process triggered by acute 
pancreatitis. In this review we describe the physiological bases and molecular 
mechanisms in the autophagic process and the possible role of autophagy in human 
disease. Understanding the events and molecular mechanisms of this complex cellular 
process will help in the design of new strategies for more effective diagnosis and 
treatment. 
 
Autophagy - VMP1 – Zymophagy -  mTOR 
 
Autophagy, a self-eating cellular process. 
 
Autophagy is an evolutionarily conserved and highly regulated lysosomal pathway 
that degrades macromolecules (e.g. proteins, glycogen, lipids and nucleotides) and 
cytoplasmic organelles (1-3). This catabolic process is involved in the turnover of 
long lived proteins and other cellular macromolecules, and it might play a protective 
role in development, aging, cell death, and defense against intracellular pathogens (4, 
5). Moreover autophagy has been linked to a variety of pathological processes such as 
neurodegenerative diseases and tumorigenesis, which highlights its biological and 
medical importance (6, 7).  
 
Autophagy consists of several sequential steps, which are: induction, autophagosome 
formation, autophagosome-lysosome fusion and degradation. Although autophagy 
was first identified in mammalian liver upon glucagon treatment approximately 50 
years ago, its molecular understanding started only in the past decade, largely based 
on the discovery of the autophagy related genes (ATG) in yeast. 
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Depending on the delivery route of the cytoplasmic material to the lysosome, there 
are three major types of autophagy in eukaryotes: 1) chaperone-mediated autophagy 
(CMA), 2) microautophagy and 3) macroautophagy, hereafter referred to as 
autophagy (8). CMA allows the direct lysosomal import of unfolded, soluble proteins 
that contain a particular pentapeptide motif. In microautophagy, cytoplasmic material 
is directly engulfed into the lysosome at the surface of the lysosome by membrane 
rearrangement. Finally, autophagy involves the sequestration of cytoplasm into a 
double-membrane cytosolic vesicle, referred to as an autophagosome that 
subsequently fuses with a lysosome to form an autolysosome for the degradation by 
lysosomal hydrolases (9). 
 
The autophagy flux 
 
Autophagy is characterized by sequestration of bulk cytoplasm and organelles in 
double-membrane vesicles called autophagosomes, which eventually acquire 
lysosomal-like features (9, 10). The autophagic process is described in the Figure 1.  
 
 
 
Figure 1. The autophagy process 
 
Briefly, sequestration of cytoplasm into a double-membrane cytosolic vesicle is 
followed by the fusion of the vesicle with a late endosome or lysosome to form an 
autophagolysosome (or autolysosome). Then, inner membrane of the autophagosome 
and autophagosome-containing cytoplasm derived materials are degraded by 
lysosomal/vacuolar hydrolases inside the autophagosome. The molecular mechanisms 
underlying the transport and fusion of autophagosomes are just beginning to be 
understood, and through active investigations, several major events involved in the 
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process have recently been clarified including the recycling of lysosomes (11). In 
mammalian cells, autophagosome maturation is a prior step for the fusion between 
autophagosomes and lysosomes. The degradation products, including macromolecules, 
are then exported to the cytosol for re-utilization by the cell.   
 
The Autophagosome Formation 
 
Since the discovery of yeast autophagy-related (ATG) proteins, autophagosome 
formation has been dissected at the molecular level but a lot of questions about the 
molecular mechanism underlying this process remain unanswered. Autophagosomes 
can be considered unique organelles because they do not contain marker proteins of 
other subcellular compartments (12). In mammalian cells, the sequential association 
of at least a subset of the ATG proteins leads to the assembly of the pre-
autophagosomal structures (PAS), which is believed to be the site where the precursor 
structure of the autophagosomes, the phagophores, are generated (13). The PAS and 
phagophore formation also requires phosphatidylinositol 3-phosphate (PI3P) (14) and 
it is believed to be associated to specific subdomains of the endoplasmic reticulum 
(ER) termed omegasomes (15, 16). Among the key mediators initiating 
autophagosome formation, there is a set of evolutionarily conserved ATG gene 
products; the kinase-containing Ulk1/2 complex (ATG1 in yeast), the Class III 
phosphatidylinositol 3-kinase (PI3K) complex (composed by BECN1/ATG6-hVps34, 
hVps15 and ATG14L), the ubiquitin-like conjugation systems leading to the formation 
of the ATG5–ATG12–ATG16L1 complex and the LC3/ ATG8 
phosphatidylethanolamine- conjugate (e.g. LC3-II) (17). A second group of ATG 
proteins, which does not have orthologous in yeast, has also recently emerged and 
appears to play a key role in regulating autophagy in high eukaryotes. One of these 
proteins is the transmembrane Vacuole-Membrane-Protein-1 (VMP1), whose 
expression triggers autophagy in mammalian cells even under nutrient-rich conditions 
(18, 19). Conversely, autophagy is completely blocked in absence of VMP1 (18). 
 
Autophagosome formation process is composed of isolation membrane nucleation, 
elongation and completion steps. In mammals, the Class III PI3K plays an essential 
role in isolation membrane nucleation during autophagy (20). The Class III PI3K is 
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associated with BECN1/ATG6 and p150, the homolog of Vps15 (phosphoinositide-3- 
kinase, regulatory subunit 4), to form the PI3K complex. This kinase catalyzes the 
generation of PI3P on the autophagosomal membrane favoring the localization of 
other ATG proteins to the PAS during autophagosomal formation. The 
autophagosome nucleation system is ATG12-ATG5-ATG16L, which is an ubiquitin-
like protein conjugation system essential for the formation of the PAS. ATG12 is 
conjugated to ATG5 (21). E1-like ATG7 activates the carboxy-terminal glycine 
residue of ATG12 through a high-energy thioester bond in an ATP-dependent manner. 
The ATG12-ATG5 conjugate further interacts with ATG16L1 to form a ~350 kDa 
multimeric ATG12-ATG5-ATG16L protein complex through the homo- 
oligomerization of ATG16L (22). Another ubiquitin-like protein conjugation system 
is the modification of LC3 (a mammalian homolog of ATG8) by the phospholipid 
phosphatidylethanolamine (PE) (22), an essential process for the formation of 
autophagosomes. LC3 (LC3-I) is cleaved by cysteine protease ATG4 and then 
conjugated with PE by ATG7 and ATG3. This lipidated LC3 (LC3-II) then associates 
with newly forming autophagosome membranes. LC3-II remains on mature 
autophagosomes until its fusion with lysosomes (23, 24). The conversion of LC3-I to 
LC3-II is thus well known as a marker of autophagy (Figure 2). However, the 
increase of LC3-II alone is not enough to show autophagy activation because the 
inhibition of LC3-II degradation in the lysosome by the impaired autophagy flux can 
also cause its accumulation.  
 
Figure 2. The conversion of LC3-I to LC3-II is thus well known as a marker of autophagy  
 
While the origin of autophagic vacuoles remains disputable, several hypotheses have 
been proposed for the source of autophagosomal membrane during autophagosome 
formation. The first hypothesis is “de novo” formation of autophagosome by ATG9 
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reservoirs. In the second hypothesis, various organelles such as ER, mitochondria and 
plasma membrane are used as an origin for the formation of the phagophore. Recently, 
cup-shaped structures called omegasome, a discrete region of the ER, were identified 
as a platform for autophagosome formation (25). The ATG5 complex, LC3 and 
ULK1 have been shown to recruit into the omegasome after starvation, and ATG5- 
and LC3-positive membranes seem to emerge from the omegasome. It was also 
observed that omegasomes form in close proximity to the PI3K- containing vesicles, 
which may synthesize the PI3P. This hypothesis is also supported by a notion of a 
physical association between the ER and early autophagic membranes (26). 
 
Regulation of autophagy induction  
 
Basal autophagy in unstressed cells is kept down by the action of the mammalian 
target of rapamycin complex 1 (mTORC1). Key upstream regulators of mTORC1 
include the class I phosphoinositide 3-kinase-Akt pathway, which keeps mTORC1 
active in cells with sufficient growth factors, and the AMP-activated protein kinase 
(AMPK) pathway that inhibits mTORC1 upon starvation and calcium signals (27, 28). 
 
Under stress conditions such as amino acid starvation, autophagy is strongly induced 
in many types of cultured cells. The effects of individual amino acids differ in their 
abilities to regulate autophagy. Amino acids including Leu, Tyr, Phe, Gln, Pro, His, 
Trp, Met and Ala suppress autophagy in ex vivo-perfused liver (29). However, such 
profiles depend on cell types showing their different amino acid metabolisms in 
tissues. The questions on how cells sense amino acid concentration and physiological 
significance of autophagy regulation by amino acid starvation are not fully understood 
yet. It has been demonstrated that amino acid signaling pathways exist, which involve 
activation of mTORC1 and the subsequent regulation of the class III PI3K. The 
mTORC1 is involved in the control of multiple cell processes in response to changes 
in nutrient conditions (30). Especially, mTORC1 requires Rag GTPase, Rheb and 
Vps34 for its activation and subsequent inhibition of autophagy in response to amino 
acids (31, 32). Energy levels are primarily sensed by AMPK, a key factor for cellular 
energy homeostasis. In low energy states, AMPK is activated and the activated 
AMPK then inactivates mTORC1 through TSC1/TSC2 and Rheb protein (33).  
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Thus, inactivation of mTORC1 is essential for the induction of autophagy and plays a 
central role in autophagy. In addition to amino acid signaling, hormones, growth 
factors and many other factors, including bcl-2 (34), have also been reported to 
regulate autophagy. But, not all autophagy signals are transduced through mTOR 
signaling. A recent study showed that small-molecule enhancers of the cytostatic 
effects of rapamycin (called SMERs) induce autophagy independently of mTOR (35). 
Activities of the ULK1 are regulated by mTOR, depending on nutrient conditions. 
Under growing and high-nutrient conditions, the active mTORC1 interacts with the 
ULK1 and phosphorylates ULK1 and mATG13, and thus inhibits the membrane 
targeting of the ULK1. During starvation condition, on the other hand, the inactivated 
mTORC1 dissociates from ULK1 and results in the ULK1 complex formation 
(ULK1-mATG13-FIP200-ATG101) leading to autophagy induction (36).  
 
BECN1 
 
BECN1 (former Beclin 1), the mammalian ATG6, is a haploinsufficient tumor 
suppressor and an important effector of autophagy. BECN1 is a subunit of the PI3K 
complex, the action of which is antagonized by Bcl-2 (36, 37).  BECN1 contains a 
BH3 domain that mediates its interaction with Bcl-2 (38, 39). The interaction between 
Bcl-2 and BECN1 leads to inhibition of autophagy by interfering with the formation 
and activity of the autophagy promoter complex, BECN1- PI3K (40). (Figure 3) 
 
 
 
 
 
 
 
 
Figure 3 BECN1-PI3K promotes autophagy 
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VMP1 
 
The pancreatitis-associated protein named vacuole membrane protein 1 (VMP1) is a 
transmembrane protein with not known homologues in yeast. VMP1 was found 
searching for new molecules that were differentially expressed during acute 
pancreatitis (41). VMP1 expression is induced by mutated K-Ras in pancreatic cancer 
cells (42) and by hyperstimulation of Gq-coupled cholecystokinin receptor (CCK-R) 
in pancreatic acinar cells during acute pancreatitis (43). In the adult normal pancreas, 
VMP1 expression is not detectable, but it is highly induced early during experimental 
acute pancreatitis and its expression levels correlate with morphological features 
resembling autophagy (44). Moreover, VMP1 expression can be found in pancreatic 
acinar cells from rats developing spontaneous chronic pancreatitis (WBN/Kob rats) 
(45) and it is rapidly and highly expressed in experimental diabetes (45-47). Finally, 
Gemcitabine (2,2-difluorodeoxycytidine), the standard chemotherapy for the 
treatment of advanced pancreatic cancer, induces VMP1 expression in human 
pancreatic cancer cells (48-50). We demonstrated that VMP1 expression triggers 
autophagosome formation in mammalian cells, even under nutrient-replete conditions 
(18, 19). Remarkable, VMP1 pancreas-specific transgenic expression in mice 
promotes autophagosome formation in acinar cells. Therefore, VMP1 expression may 
be involved in autophagy induction during acute pancreatitis, a disease defined as 
pancreas self-digestion. Furthermore, VMP1 is the only human disease-inducible 
ATG-protein described so far.  
 
VMP1 interacts with BECN1 through its hydrophilic C-terminal region (VMP1-
ATGD), which is necessary for early steps of autophagosome formation. Hierarchical 
analyses in mammalian cells shows that VMP1 along with ULK1 localize in the 
autophagosome formation site (13). VMP1-BECN1 interaction is required for the 
formation of the PI3K complex acting in mammalian autophagy. This complex, which 
is composed by BECN1-hVps34-ATG14 promotes PI3P generation on 
autophagosomal membrane favoring the localization of ATG16L1 and LC3 to the 
autophagosomal membrane during autophagosome formation (51, 52). The 
interaction between VMP1 and BECN1 requires the BECN1 domain that binds to 
Bcl2 (BECN1-BH3 domain) (51). During normal growth conditions Bcl-2 binding to 
BECN1 is maximal, and when autophagy is induced this interaction is strongly 
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reduced (53). VMP1 expression leads to the dissolution of the BECN1-Bcl-2 complex, 
indicating that VMP1 is involved in driving BECN1 into the autophagic process (38). 
Thus, VMP1-BECN1 interaction through the VMP1-ATGD is required for the proper 
localization of PI3K activity on the autophagosomal membrane during mammalian 
autophagy, positioning VMP1 as a key regulator of the early steps of autophagosome 
formation possibly acting as a platform in the autophagosomal membrane. 
 
Selective types of Autophagy  
 
Early studies suggested that autophagy was a nonselective process in which 
cytoplasmic structures were randomly sequestered into autophagosomes before being 
delivered to the mammalian lysosome or the plant and yeast vacuole for degradation. 
Now there is growing evidence that unwanted cellular structures can be selectively 
recognized and exclusively eliminated within cells. This is achieved through the 
action of specific autophagy receptors, such as Nbr1 and p62, which is an ubiquitin-
binding protein that interacts with LC3 (54-55). Thus excess or damaged organelles 
including mitochondria, peroxisomes, lipid droplets, endoplasmic reticulum and 
ribosomes can be specifically sequestered by autophagosomes and targeted to the 
lysosome for degradation. Importantly, there is growing evidence that selective 
autophagy subtypes also have a wide range of physiological functions. Selective 
autophagic pathways target distinct cargoes to autophagosomes, including 
mechanisms for the clearance of aggregated protein, and for the removal of 
dysfunctional mitochondria (mitophagy). In pancreas cells, autophagy has recently 
been shown to specifically turn over secretory granules damaged by acute pancreatitis 
as a protective cellular response (43).  
 
Zymophagy  
 
The pancreatic acinar cell activates VMP1-mediated autophagy early during acute 
pancreatitis (44). Relevant data about the role of autophagy in pancreas was obtained 
using ElaI-VMP1 mice, in which the pancreas acinar-cell-specific elastase promoter 
drives VMP1 expression in pancreas. Pancreases of these transgenic mice show 
numerous vesicles that stain for endogenous LC3, indicating that VMP1 induces the 
autophagosome formation and, therefore, autophagy (18). Interestingly, ElaI-VMP1 
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mice do not develop pancreatitis in normal conditions, confirming that 
autophagosome formation does not induce acute pancreatitis (18). The 
immunomagnetic isolation of VMP1-autophagosomes containing zymogen granules 
from the ElaI-VMP1 transgenic mouse pancreas with acute pancreatitis, allowed the 
discovery of a new type of selective autophagy named zymophagy, which functions 
as an inducible cellular process that recognizes and degrades activated zymogen 
granules (43).  
 
Zymophagy is characterized by the formation of autophagosomes containing 
zymogen granules. These organelles mediate the sequestration and degradation of 
pancreatitis activated zymogen granules. Cholecistokinin receptor (CCK-R) 
hyperstimulation with cerulein in wild-type animals, a classical model of acute 
pancreatitis, induced a markedly altered distribution pattern of the secretory granules 
such as fusion among zymogen granules as well as their fusion with condensing 
vacuoles. In addition, acinar cells lose their polarity, which results in the relocation of 
zymogen granules to the basolateral membrane. Surprisingly, ElaI-VMP1 mice 
subjected to CCK-R hyperstimulation reveal that acinar cells preserve their structure 
and polarity with negligible or no alteration in vesicular transport. Instead, pancreases 
from cerulein-treated ElaIVMP1 mice present autophagosomes containing zymogen 
granules displaying a distinct localization to the apical area of the acinar cell. This 
observation is confirmed using isolated mouse pancreas acini, revealing that 15 min 
after cerulein treatment, zymophagy is detected (43). The finding of different 
maturation levels of selective autophagic vesicles as well as the degradation of p62 
provide evidence that autophagic flow remains primarily unchanged under CCK-R 
hyperstimulation (43) 
 
Regarding the pathophysiological relevance of zymophagy during acute pancreatitis, 
it was demonstrated that zymophagy protects acinar cells from intracellular 
trypsinogen activation triggered in vivo by experimental pancreatitis induced by 
cerulein. Upon CCK-R hyperstimulation, wild type mice developed acute pancreatitis 
with high amylase and lipase serum levels. On the contrary, enzymatic levels in 
cerulein-treated ElaI-VMP1 mice were significantly lower compared with wild type 
mice. Consistently, ElaI-VMP1 mouse pancreas showed remarkably less macroscopic 
evidence of acute pancreatitis compared with wild type animals, which showed 
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marked edema and hemorrhage. Histological analyses displayed a high degree of 
necrosis as well as infiltration in wild type pancreas with acute pancreatitis. In 
contrast, neither necrosis nor significant inflammation was seen in cerulein-treated 
ElaI-VMP1 mice (41, 43). Thus, results obtained in the transgenic animal model 
showed that zymophagy functions as a protective pathophysiological mechanism 
against pancreatitis-associated injury.  
 
Upon CCK-R hyperstimulation, acinar cells from wild-type mice show early 
cytoplasmic trypsinogen activation, which is a hallmark of pancreatitis 
pathophysiology. Surprisingly, in acinar cells from ElaI-VMP1 mice, CCK 
hyperstimulation causes almost no activation of trypsinogen. Microscopic 
examinations using BZiPAR (rhodamine 110 bis-(CBZ-L-isoleucyl-L-prolyl-L-
arginine amide) dihydrochloride), a cell permeable substrate that becomes fluorescent 
after the cleavage by the protease, reveal only few activated granules that highly 
colocalize with VMP1, showing that zymophagy selectively sequester the activated 
zymogen granules. Zymogen activation is an enzymatic chain reaction where initial 
zymogen granule alterations trigger rapid spread of active trypsin within the acinar 
cell. We think that the degradation of early-activated zymogen granules by 
zymophagy prevents this deleterious event. Interestingly, the inhibition of autophagic 
flow markedly increases trypsin activity within acinar cells in ElaI-VMP1 mouse 
pancreases under CCK-R hyperstimulation, confirming that zymophagy specifically 
degrades those zymogen granules that are initially activated by acute pancreatitis (43). 
This function is confirmed in the in vivo animal model of acute pancreatitis, where 
the ability of the ElaI-VMP1 mouse developing zymophagy clearly prevents the 
increment of enzymatic markers of pancreatic damage and pancreas morphological 
changes characteristic of acute pancreatitis. 
 
Analysis of autophagosomes containing zymogen granules magnetically 
immunopurified from the pancreas of ElaI-VMP1 mice treated with cerulein revealed 
that apart from zymogen granules, isolated vesicles contains LC3-II and, notably, 
strong signals of p62. Moreover, GFP-Ubiquitin-transfected acinar cells subjected to 
CCK-R hyperstimulation show co-localization between activated granules and 
ubiquitin aggregates but do not show colocalization between unaffected or normal 
zymogen granules and ubiquitin, indicating that the ubiquitin system serves as a 
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targeting signal for activated zymogen granules during zymophagy. Therefore, 
activated zymogen granules are directly or indirectly ubiquitinated for their 
recognition by autophagic membranes, in which ubiquitin acts as a label for selective 
engulfment. Nevertheless, activated zymogen granules are ubiquitinated upon acute 
pancreatitis and the VMP1-mediated selective autophagic pathway sequesters these 
ubiquitinated granules (43). p62 may function as a cargo receptor during zymophagy. 
This data demonstrates for the first time that ubiquitin modifications may possess an 
additional function in acinar cells by promoting the degradation of highly harmful 
activated zymogen granules (56) (Figure 4). 
 
 
 
 
Figure 4. Zymophagy: The selective type of autophagy that sequesters and degrades activated 
zymogen granules (red circles) mediated by VMP1 expression, early during acute pancreatitis.  
 
Zymophagy prevents pancreatic acinar cell death induced by CCK-R 
hyperstimulation (43). Autophagosome formation inhibition with 3-methyl adenine as 
well as autophagy flux interruption with vinblastine significantly reduces acinar cell 
survival in a cell model of acute pancreatitis. Moreover, VMP1 downregulation 
(shVMP1) also significantly decreases acinar cell survival under CCK 
hyperstimulation showing that VMP1 expression and autophagy is required to prevent 
acinar cell death in acute pancreatitis. These results indicate that zymophagy prevents 
pancreatic cell death induced by the activation of zymogen granules (56) and confirm 
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that endogenous VMP1 expression is activated in acinar cells to mediate zymophagy 
as a protective cellular response against cell death. 
 
Furthermore, VMP1 expression and zymophagy are present in human pancreas 
affected by acute pancreatitis (43, 56). VMP1 is not detectable in human normal 
pancreas tissue, but its expression is activated in human pancreatitis pancreas 
specimens and highly colocalizes with LC3 in autophagosomes. Moreover, 
autophagosomes markedly colocalize with zymogen granules. Remarkable, the 
finding of large autolysosomes without trypsin signal in pancreas of human 
pancreatitis suggests that affected zymogen granules are eventually degraded by 
zymophagy during human pancreatitis. 
 
Perspectives 
 
There is ample evidence supporting an active role for autophagy in cell physiology 
and disease. During the last decade, autophagy has turned from a morphological 
finding to a cellular process involving a membrane transport system and complex 
molecular machinery. Moreover, since the discovery of ATG genes, there have been 
many studies on the physiological and pathological roles of autophagy in a variety of 
autophagy knockout models. However, direct evidence of the connections between 
ATG gene dysfunction and human diseases has emerged only recently (57). Here we 
have overviewed the physiological bases and molecular mechanisms of the 
autophagic process. We have introduced the reader to a novel autophagy-related 
transmembrane protein -VMP1- whose expression triggers autophagy and to the role 
of this protein in the cell response to disease.  Elucidation of the specific extracellular 
and intracellular conditions that stimulate autophagy and the linkage of these 
conditions to either cell survival or cell injury and death in different cell types and 
during different pathological processes, is a rapidly evolving and fruitful field of 
research. The development of therapies to take advantage of the potential 
cytoprotective effect of autophagy in several pathologies such as cancer or 
neurodegenerative diseases is a potentially promising avenue of investigation. 
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